Earnings Feed
Start Free
Home/Filings/3/0001415889-21-000405
3//SEC Filing

Checkmate Strategic Capital 2, LLC 3

Accession 0001415889-21-000405

CIK 0001310527other
View on SEC.govCompany Profile

Filed

Jan 26, 7:00 PM ET

Accepted

Jan 27, 9:29 PM ET

Size

21.1 KB

Accession

0001415889-21-000405

Insider Transaction Report

Form 3
Period: 2021-01-15
QSAM Biosciences, Inc.QSAM
Checkmate Strategic Capital Holdings, LLC
Other
Holdings

  • Common Stock

    762,088

  • Series B Convertible Preferred Stock

    Exercise: $0.16From: 2021-01-15→ Common Stock (975,000 underlying)

  • Warrants

    Exercise: $0.45From: 2021-01-15Exp: 2022-01-14→ Common Stock (475,000 underlying)

  • Common Stock

    (indirect: See Footnote)
    6,217,599

  • Warrants

    (indirect: See Footnote)
    Exercise: $0.45From: 2021-01-15Exp: 2022-01-14→ Common Stock (107,825 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See Footnote)
    Exercise: $0.16From: 2021-01-15→ Common Stock (1,912,500 underlying)

  • Common Stock

    6,044,605
Checkmate Strategic Capital 2, LLC
10% OwnerOther
Holdings

  • Series B Convertible Preferred Stock

    Exercise: $0.16From: 2021-01-15→ Common Stock (975,000 underlying)

  • Warrants

    (indirect: See Footnote)
    Exercise: $0.45From: 2021-01-15Exp: 2022-01-14→ Common Stock (107,825 underlying)

  • Common Stock

    (indirect: See Footnote)
    6,217,599

  • Common Stock

    6,044,605

  • Common Stock

    762,088

  • Series B Convertible Preferred Stock

    (indirect: See Footnote)
    Exercise: $0.16From: 2021-01-15→ Common Stock (1,912,500 underlying)

  • Warrants

    Exercise: $0.45From: 2021-01-15Exp: 2022-01-14→ Common Stock (475,000 underlying)
Checkmate Capital Group, LLC
Other
Holdings

  • Common Stock

    762,088

  • Common Stock

    (indirect: See Footnote)
    6,217,599

  • Series B Convertible Preferred Stock

    (indirect: See Footnote)
    Exercise: $0.16From: 2021-01-15→ Common Stock (1,912,500 underlying)

  • Warrants

    (indirect: See Footnote)
    Exercise: $0.45From: 2021-01-15Exp: 2022-01-14→ Common Stock (107,825 underlying)

  • Common Stock

    6,044,605

  • Warrants

    Exercise: $0.45From: 2021-01-15Exp: 2022-01-14→ Common Stock (475,000 underlying)

  • Series B Convertible Preferred Stock

    Exercise: $0.16From: 2021-01-15→ Common Stock (975,000 underlying)
Paschall Charles Thomas
Other
Holdings

  • Common Stock

    762,088

  • Warrants

    Exercise: $0.45From: 2021-01-15Exp: 2022-01-14→ Common Stock (475,000 underlying)

  • Warrants

    (indirect: See Footnote)
    Exercise: $0.45From: 2021-01-15Exp: 2022-01-14→ Common Stock (107,825 underlying)

  • Series B Convertible Preferred Stock

    (indirect: See Footnote)
    Exercise: $0.16From: 2021-01-15→ Common Stock (1,912,500 underlying)

  • Series B Convertible Preferred Stock

    Exercise: $0.16From: 2021-01-15→ Common Stock (975,000 underlying)

  • Common Stock

    (indirect: See Footnote)
    6,217,599

  • Common Stock

    6,044,605
Footnotes (12)
  • [F1]This Form 3 is filed jointly by Charles Thomas Paschall, Checkmate Strategic Capital 2, LLC, Checkmate Capital Group, LLC, and Checkmate Strategic Capital Holdings, LLC (collectively, the "Reporting Persons").
  • [F10]Mr. Paschall is a member of Checkmate Capital Group, LLC, holding 22.7% of its membership interest, as of January 27, 2021. As such, Mr. Paschall has a proportional pecuniary interest in the warrants beneficially owned by Checkmate Capital Group, LLC.
  • [F11]Warrants beneficially owned by Checkmate Capital Group, LLC.
  • [F12]Shares of Series B Convertible Preferred Stock beneficially owned by Checkmate Strategic Capital Holdings, LLC.
  • [F2]Each Reporting Person is a member of a Section13(d) group that owns in the aggregate more than 10% of the Issuer's outstanding shares of Common Stock, as disclosed in a Schedule 13D, filed on behalf of the Reporting Persons on January 26, 2021. As such, each Reporting Person may be deemed to beneficially own more than 10% of the Issuer's outstanding shares of Common Stock.
  • [F3]Mr. Paschall is the sole member of Checkmate Strategic Capital 2, LLC, and a member holding (as of January 27, 2021) 22.7% membership interest of Checkmate Capital Group, LLC. Checkmate Strategic Capital 2, LLC and Checkmate Capital Group, LLC beneficially own 6,044,605 and 762,088 shares of Common Stock, respectively. As such, Mr. Paschall beneficially owns 6,217,599 shares of Common Stock, calculated on a pro-rata basis with respect to Checkmate Capital Group, LLC.
  • [F4]Shares of Common Stock beneficially owned by Checkmate Strategic Capital 2, LLC.
  • [F5]Shares of Common Stock beneficially owned by Checkmate Capital Group, LLC.
  • [F6]Series B Convertible Preferred Stock is convertible into Common Stock pursuant to terms of the Certificate of Designation filed by the Issuer on December 29, 2020.
  • [F7]Mr. Paschall is the sole member of Checkmate Strategic Capital 2, LLC, which is a controlling member of Checkmate Strategic Capital Holdings, LLC. As such, Mr. Paschall is deemed to beneficially own the Series B Convertible Preferred Stock owned by these entities, convertible into 1,912,500 shares of Common Stock.
  • [F8]Checkmate Strategic Capital 2, LLC is a controlling member of Checkmate Strategic Holdings, LLC. As such, Checkmate Strategic Capital 2, LLC beneficially owns Series B Convertible Preferred Stock owned by Checkmate Strategic Holdings, LLC, convertible into 937,500 shares of Common Stock.
  • [F9]Shares of Series B Convertible Preferred Stock beneficially owned by Checkmate Strategic Capital 2, LLC.

Documents

1 file

Issuer

QSAM Biosciences, Inc.

CIK 0001310527

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001842521

Filing Metadata

Form type
3
Filed
Jan 26, 7:00 PM ET
Accepted
Jan 27, 9:29 PM ET
Size
21.1 KB
View on SEC.gov